tuneTypical Dose
About 300-600 GalU per meal containing trigger foods. This is the most commonly effective range in the clinical literature.
Digestive Enzyme
Alpha-Galactosidase
Alpha-galactosidase (EC 3.2.1.22)
Evidence TierCWADA NOT PROHIBITED
watchEffect Window
Alpha-galactosidase acts within the same meal. Gas reduction occurs over the 4-8 hours following the treated meal. There is no cumulative or delayed effect.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Alpha-galactosidase is a digestive enzyme that breaks down gas-producing oligosaccharides in beans, legumes, and cruciferous vegetables before they reach the colon and cause bloating and flatulence.
Alpha-galactosidase works by hydrolyzing the alpha-1,6-galactosidic bonds in raffinose, stachyose, and verbascose, oligosaccharides that humans cannot digest on their own. When these sugars pass intact to the colon, gut bacteria ferment them and produce gas. Taking the enzyme with the first bite of a trigger meal breaks down these oligosaccharides in the upper GI tract before they ever reach the colon. The evidence base is small but mechanistically clean in bean-challenge studies, with crossover trials showing reduced breath hydrogen and symptom scores after trigger meals. The IBS evidence is less consistent, with one GOS-sensitive subgroup trial showing benefit and a later placebo-controlled pilot showing no clear effect. Safety is excellent, with galactosemia and Aspergillus allergy as the main contraindications.
Alpha-galactosidase hydrolyzes alpha-1,6-galactosidic bonds in raffinose-series oligosaccharides (raffinose, stachyose, verbascose) in the stomach and proximal small intestine. This prevents intact oligosaccharides from reaching the colon, where bacterial fermentation would produce hydrogen, carbon dioxide, and methane gas. The enzyme is derived from Aspergillus niger fermentation and acts locally in the GI lumen without meaningful systemic absorption.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Reduced gas production and gas-related symptoms (bloating, flatulence) after meals containing beans, legumes, and other oligosaccharide-rich foods
Secondary Outcomes
- Improved tolerance to high-GOS foods in GOS-sensitive IBS patients as an adjunct to dietary management
- Reduced breath hydrogen excretion as an objective marker of decreased colonic oligosaccharide fermentation
Safety
Contraindications and Interactions
Contraindications
- Galactosemia
- Aspergillus niger or mold allergy
Side effects
- Allergic reaction (very rare)
- Mild GI discomfort
Interactions
No entries provided
Avoid if
- Diagnosed with galactosemia or a galactose metabolism disorder
- Known allergy to Aspergillus niger, mold-derived products, or penicillin-family mold allergens
Evidence
Study-level References
alpha-galactosidase-SRC-001Randomized, double-blind, placebo-controlled crossover trial
Sourceopen_in_newDi Stefano M, Miceli E, Gotti S, Missanelli A, Mazzocchi S, Corazza GR. The effect of oral alpha-galactosidase on intestinal gas production and gas-related symptoms. Dig Dis Sci. 2007;52(1):78-83.
Population: Eight healthy adult volunteers consuming a bean-challenge meal
Dose protocol: 300 or 1200 GalU vs placebo during a 420g cooked bean meal in a crossover design
Key findings: 1200 GalU significantly reduced breath hydrogen excretion and flatulence severity. Both 300 and 1200 GalU reduced total symptom score.
Notes: The most mechanistically informative study. Small sample (n=8) but strong within-subject crossover design and objective endpoint.
Paper content
Key crossover trial demonstrating that oral alpha-galactosidase reduces both objective (breath hydrogen) and subjective (symptom score) markers of intestinal gas production after a standardized bean meal in healthy volunteers. The higher dose (1200 GalU) produced significant reductions in breath hydrogen excretion and flatulence severity, while both the 300 and 1200 GalU doses reduced the composite symptom score. The crossover design strengthens internal validity despite the small sample size (n=8). This study provides the most direct mechanistic and symptomatic evidence for alpha-galactosidase in healthy humans eating a defined oligosaccharide-rich meal.
alpha-galactosidase-SRC-002Randomized, double-blind, placebo-controlled crossover trial
Sourceopen_in_newGaniats TG, Norcross WA, Halverson AL, Burford PA, Palinkas LA. Does Beano prevent gas? A double-blind crossover study of oral alpha-galactosidase to treat dietary oligosaccharide intolerance. J Fam Pract. 1994;39(5):441-445.
Population: Nineteen healthy adult volunteers consuming meatless chili containing beans
Dose protocol: Standard Beano dose (15 drops) vs placebo with meatless bean chili in crossover design
Key findings: Significantly fewer flatulence events per hour (p=0.016). Subjective severity of flatulence and bloating did not reach significance.
Notes: The original Beano RCT. Industry-funded. Established proof of concept but with limited subjective symptom capture.
Paper content
The original Beano RCT and one of the earliest controlled studies of oral alpha-galactosidase for dietary oligosaccharide intolerance. The crossover design found that alpha-galactosidase significantly reduced the number of flatulence events per hour during the 6-hour postprandial window (F = 2.87, p = 0.016). However, the subjective severity ratings for flatulence and bloating did not reach significance. This dissociation between event frequency and perceived severity is a recurring theme in the alpha-galactosidase literature and highlights the difficulty of capturing subjective symptom relief in small crossover studies. Despite limitations, this trial established the basic proof of concept that exogenous alpha-galactosidase taken with a bean meal can measurably reduce gas production in humans.
alpha-galactosidase-SRC-003Randomized, double-blind, placebo-controlled crossover trial
Sourceopen_in_newTuck CJ, Taylor KM, Gibson PR, Barrett JS, Muir JG. Increasing symptoms in irritable bowel symptoms with ingestion of galacto-oligosaccharides are mitigated by alpha-galactosidase treatment. Am J Gastroenterol. 2018;113(1):124-134.
Population: Thirty-one adults with IBS (Rome III criteria) completing the full protocol, with 21 classified as GOS-sensitive
Dose protocol: 150 or 300 GALU vs placebo with high-GOS meals in IBS patients, crossover design
Key findings: Full-dose (300 GALU) reduced overall symptoms and bloating in GOS-sensitive IBS patients (21 of 31 completers). No benefit in non-GOS-sensitive patients.
Notes: The most clinically relevant trial. Conducted by the Monash FODMAP group. Confirms that benefit depends on matching the enzyme to the actual dietary trigger.
Paper content
The most clinically relevant alpha-galactosidase trial in a symptomatic population. This Monash University study tested alpha-galactosidase as an adjunct to FODMAP dietary management in IBS patients. The key insight is that benefit was restricted to the GOS-sensitive subgroup (21 of 31 completers). In those patients, full-dose enzyme (300 GALU) significantly reduced overall symptoms and bloating when co-ingested with high-GOS meals. The half dose (150 GALU) did not consistently reach significance. Importantly, when all IBS completers were analyzed together (including non-GOS-sensitive patients), the benefit was diluted and not significant. This supports the mechanistic specificity of alpha-galactosidase, meaning it helps when the symptom trigger is actually galacto-oligosaccharides, not when IBS symptoms arise from other FODMAP categories or non-dietary mechanisms. The study is particularly valuable because it was conducted by the group that developed the low-FODMAP diet framework and directly tested enzyme therapy as a practical dietary adjunct.
alpha-galactosidase-SRC-004Randomized, double-blind, placebo-controlled trial.
Sourceopen_in_newDi Nardo G, Oliva S, Ferrari F, Mallardo S, Barbara G, Cremon C, Aloi M, Cucchiara S. Efficacy and tolerability of alpha-galactosidase in treating gas-related symptoms in children: a randomized, double-blind, placebo controlled trial. BMC Gastroenterol. 2013;13:142. doi:10.1186/1471-230X-13-142. PMID:24063420.
Population: Children aged 4 to 17 years with chronic gas-related symptoms including bloating, flatulence, and abdominal distension.
Dose protocol: Weight-based alpha-galactosidase drops or tablets versus placebo for 2 weeks in children aged 4 to 17.
Key findings: Significant reduction in global distress (p=0.02), moderate-to-severe bloating days (p=0.03), and flatulence proportion (p=0.02). No adverse events reported.
Notes: The only published RCT in a pediatric population with chronic gas symptoms. Small sample (n=52) but well-designed double-blind placebo-controlled trial with consistent results across endpoints.
Paper content
This pediatric RCT enrolled 52 children with chronic gas-related symptoms and randomized them to alpha-galactosidase or placebo for 2 weeks. The enzyme significantly reduced global distress (p=0.02), moderate-to-severe bloating days (p=0.03), and flatulence proportion (p=0.02). No adverse events were reported. This is the only published RCT testing alpha-galactosidase in a pediatric population with chronic gas symptoms, supporting its safety and tolerability in children.
alpha-galactosidase-SRC-005Randomized, double-blind, placebo-controlled crossover pilot study
Sourceopen_in_newBöhn L, Törnblom H, Van Oudenhove L, Simrén M, Störsrud S. A randomized double-blind placebo-controlled crossover pilot study: Acute effects of the enzyme α-galactosidase on gastrointestinal symptoms in irritable bowel syndrome patients. Neurogastroenterol Motil. 2021;33(7):e14094. doi:10.1111/nmo.14094. PMID:33619835.
Population: Adults with irritable bowel syndrome
Dose protocol: 1200 GaIU with three standardized oligosaccharide-rich meals in a randomized, double-blind crossover IBS pilot
Key findings: In 20 adults with IBS, alpha-galactosidase was not superior to placebo for postprandial symptoms or breath hydrogen and methane responses.
Notes: Important corrective study because it limits how confidently bean-meal results can be generalized to IBS.
Paper content
This randomized double-blind crossover pilot enrolled 20 adults with IBS and tested alpha-galactosidase 1200 GaIU per meal against placebo during three standardized oligosaccharide-rich meals. Symptoms rose after the meals on both study days, but neither symptom ratings nor breath hydrogen and methane differed between alpha-galactosidase and placebo. The study is a useful corrective because it suggests that the cleaner bean-challenge and GOS-sensitive subgroup results do not automatically generalize to broader IBS populations.